Literature DB >> 24366230

Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field.

Miriam B Vos1.   

Abstract

PURPOSE OF REVIEW: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and it has overlapping pathogenesis with diabetes and cardiovascular disease. Reviewed here are recent advances in understanding the contribution of diet and selected nutrients to NAFLD. RECENT
FINDINGS: To understand the effect of diet, the microbiome must be considered because it is the interface of diet and the liver. Early studies suggest that the characteristic of the microbiota is altered in NAFLD. Fructose is a lipogenic carbohydrate that contributes to insulin resistance, hypertriglyceridemia and appears to be associated with the severity of NAFLD. Fructose absorption and malabsorption may alter the microbiota and could be mediating effects on the liver. Lipids also have potent microbiome interactions and could contribute to the benefit of diets emphasizing lipid changes. Several new studies demonstrate that the Mediterranean diet and 'lifestyle change' are effective in modestly improving NAFLD. A new study of 'lifestyle' in children showed simultaneous improvement in cardiovascular disease risk measurements and hepatic steatosis.
SUMMARY: Current data supports limiting sugar in the diet and 'lifestyle change' as a first-line treatment for NAFLD; however, the benefits from these appear to be modest. The effects of diet on the liver are mediated through the microbiome and expansion of research in this area is needed.

Entities:  

Mesh:

Year:  2014        PMID: 24366230      PMCID: PMC3947892          DOI: 10.1097/MOL.0000000000000043

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  39 in total

1.  Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model.

Authors:  Sabine Wagnerberger; Astrid Spruss; Giridhar Kanuri; Carolin Stahl; Markus Schröder; Walter Vetter; Stephan C Bischoff; Ina Bergheim
Journal:  J Nutr Biochem       Date:  2012-06-27       Impact factor: 6.048

Review 2.  Extrahepatic complications of nonalcoholic fatty liver disease.

Authors:  Matthew J Armstrong; Leon A Adams; Ali Canbay; Wing-Kin Syn
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

3.  Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD.

Authors:  Ran Jin; Ngoc-Anh Le; Shuling Liu; Monica Farkas Epperson; Thomas R Ziegler; Jean A Welsh; Dean P Jones; Craig J McClain; Miriam B Vos
Journal:  J Clin Endocrinol Metab       Date:  2012-04-27       Impact factor: 5.958

4.  Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

Authors:  Luca Miele; Venanzio Valenza; Giuseppe La Torre; Massimo Montalto; Giovanni Cammarota; Riccardo Ricci; Roberta Mascianà; Alessandra Forgione; Maria L Gabrieli; Germano Perotti; Fabio M Vecchio; Gianlodovico Rapaccini; Giovanni Gasbarrini; Chris P Day; Antonio Grieco
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

5.  High rates of fructose malabsorption are associated with reduced liver fat in obese African Americans.

Authors:  Ryan W Walker; Kim-Anne Lê; Jaime Davis; Tanya L Alderete; Rebecca Cherry; Sylvie Lebel; Michael I Goran
Journal:  J Am Coll Nutr       Date:  2012-10       Impact factor: 3.169

6.  Antibiotics in early life alter the murine colonic microbiome and adiposity.

Authors:  Ilseung Cho; Shingo Yamanishi; Laura Cox; Barbara A Methé; Jiri Zavadil; Kelvin Li; Zhan Gao; Douglas Mahana; Kartik Raju; Isabel Teitler; Huilin Li; Alexander V Alekseyenko; Martin J Blaser
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

Review 7.  Dietary fructose in nonalcoholic fatty liver disease.

Authors:  Miriam B Vos; Joel E Lavine
Journal:  Hepatology       Date:  2013-05-01       Impact factor: 17.425

8.  Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease.

Authors:  Meropi D Kontogianni; Nafsika Tileli; Aikaterini Margariti; Michael Georgoulis; Melanie Deutsch; Dina Tiniakos; Elisabeth Fragopoulou; Rodessa Zafiropoulou; Yannis Manios; George Papatheodoridis
Journal:  Clin Nutr       Date:  2013-09-07       Impact factor: 7.324

9.  Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome.

Authors:  Miguel A Lanaspa; Takuji Ishimoto; Nanxing Li; Christina Cicerchi; David J Orlicky; Philip Ruzycki; Philip Ruzicky; Christopher Rivard; Shinichiro Inaba; Carlos A Roncal-Jimenez; Elise S Bales; Christine P Diggle; Aruna Asipu; J Mark Petrash; Tomoki Kosugi; Shoichi Maruyama; Laura G Sanchez-Lozada; James L McManaman; David T Bonthron; Yuri Y Sautin; Richard J Johnson
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men.

Authors:  Richard D Johnston; Mary C Stephenson; Hannah Crossland; Sally M Cordon; Elisa Palcidi; Eleanor F Cox; Moira A Taylor; Guruprasad P Aithal; Ian A Macdonald
Journal:  Gastroenterology       Date:  2013-07-19       Impact factor: 22.682

View more
  13 in total

1.  Pediatric Fatty Liver Disease.

Authors:  Ajay Jain
Journal:  Mo Med       Date:  2019 Mar-Apr

2.  Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?

Authors:  Giovanni Musso
Journal:  Diabetologia       Date:  2014-02-20       Impact factor: 10.122

3.  Amino Acid Metabolism is Altered in Adolescents with Nonalcoholic Fatty Liver Disease-An Untargeted, High Resolution Metabolomics Study.

Authors:  Ran Jin; Sophia Banton; ViLinh T Tran; Juna V Konomi; Shuzhao Li; Dean P Jones; Miriam B Vos
Journal:  J Pediatr       Date:  2016-02-05       Impact factor: 4.406

Review 4.  Nonhuman Primates and Translational Research-Cardiovascular Disease.

Authors:  Laura A Cox; Michael Olivier; Kimberly Spradling-Reeves; Genesio M Karere; Anthony G Comuzzie; John L VandeBerg
Journal:  ILAR J       Date:  2017-12-01

Review 5.  Hepatic glucose and lipid metabolism.

Authors:  John G Jones
Journal:  Diabetologia       Date:  2016-04-05       Impact factor: 10.122

Review 6.  Epigenetic effects of human breast milk.

Authors:  Elvira Verduci; Giuseppe Banderali; Salvatore Barberi; Giovanni Radaelli; Alessandra Lops; Federica Betti; Enrica Riva; Marcello Giovannini
Journal:  Nutrients       Date:  2014-04-24       Impact factor: 5.717

Review 7.  Assessment of cardiometabolic risk in children in population studies: underpinning developmental origins of health and disease mother-offspring cohort studies.

Authors:  R-C Huang; Susan L Prescott; Keith M Godfrey; Elizabeth A Davis
Journal:  J Nutr Sci       Date:  2015-04-10

8.  Fructose Malabsorption in Systemic Sclerosis.

Authors:  Isabelle Marie; Anne-Marie Leroi; Guillaume Gourcerol; Hervé Levesque; Jean-François Ménard; Philippe Ducrotte
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

9.  Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.

Authors:  Jennifer E Lambert; Jill A Parnell; Bertus Eksteen; Maitreyi Raman; Marc R Bomhof; Kevin P Rioux; Karen L Madsen; Raylene A Reimer
Journal:  BMC Gastroenterol       Date:  2015-12-03       Impact factor: 3.067

10.  miR-149 controls non-alcoholic fatty liver by targeting FGF-21.

Authors:  Junjie Xiao; Dongchao Lv; Yingying Zhao; Xiaoyu Chen; Meiyi Song; Jingqi Liu; Yihua Bei; Fei Wang; Wenzhuo Yang; Changqing Yang
Journal:  J Cell Mol Med       Date:  2016-04-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.